Hill J C, Diamond O J, O'Brien S, Boldt J G, Stevenson M, Beverland D E
Musgrave Park Hospital, Stockman's Lane, Belfast, BT9 7JB, UK.
Private Hospital Worbstrasse, 324 CH 3073 Guemligen, Switzerland.
Bone Joint J. 2015 Mar;97-B(3):300-5. doi: 10.1302/0301-620X.97B3.33242.
Ceramic-on-metal (CoM) is a relatively new bearing combination for total hip arthroplasty (THA) with few reported outcomes. A total of 287 CoM THAs were carried out in 271 patients (mean age 55.6 years (20 to 77), 150 THAs in female patients, 137 in male) under the care of a single surgeon between October 2007 and October 2009. With the issues surrounding metal-on-metal bearings the decision was taken to review these patients between March and November 2011, at a mean follow-up of 34 months (23 to 45) and to record pain, outcome scores, radiological analysis and blood ion levels. The mean Oxford Hip Score was 19.2 (12 to 53), 254 patients with 268 hips (95%) had mild/very mild/no pain, the mean angle of inclination of the acetabular component was 44.8(o) (28(o) to 63(o)), 82 stems (29%) had evidence of radiolucent lines of > 1 mm in at least one Gruen zone and the median levels of cobalt and chromium ions in the blood were 0.83 μg/L (0.24 μg/L to 27.56 μg/L) and 0.78 μg/L (0.21 μg/L to 8.84 μg/L), respectively. The five-year survival rate is 96.9% (95% confidence interval 94.7% to 99%). Due to the presence of radiolucent lines and the higher than expected levels of metal ions in the blood, we would not recommend the use of CoM THA without further long-term follow-up. We plan to monitor all these patients regularly.
陶瓷对金属(CoM)是全髋关节置换术(THA)中一种相对较新的轴承组合,相关报道的结果较少。2007年10月至2009年10月期间,在一位外科医生的治疗下,共对271例患者(平均年龄55.6岁(20至77岁),女性患者150例THA,男性患者137例)进行了287例CoM THA手术。鉴于金属对金属轴承存在的问题,于2011年3月至11月对这些患者进行了复查,平均随访34个月(23至45个月),并记录疼痛情况、疗效评分、放射学分析和血液离子水平。牛津髋关节平均评分为19.2(12至53),254例患者的268个髋关节(95%)有轻度/非常轻度/无疼痛,髋臼组件的平均倾斜角度为44.8°(28°至63°),82个股骨柄(29%)在至少一个Gruen区有大于l mm的透亮线证据,血液中钴和铬离子的中位数水平分别为0.83μg/L(0.24μg/L至27.56μg/L)和0.78μg/L(0.21μg/L至8.84μg/L)。五年生存率为96.9%(95%置信区间94.7%至99%)。由于存在透亮线以及血液中金属离子水平高于预期,在没有进一步长期随访的情况下,我们不建议使用CoM THA。我们计划定期对所有这些患者进行监测。